Switch theme
Sign up to access all valuation multiples
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
2005
87
LTM Revenue $20.0M
LTM EBITDA -$5.8M
$94.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cyclopharm has a last 12-month revenue of $20.0M and a last 12-month EBITDA of -$5.8M.
In the most recent fiscal year, Cyclopharm achieved revenue of $16.7M and an EBITDA of -$2.0M.
Cyclopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cyclopharm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.7M | $16.7M | XXX | XXX | XXX |
| Gross Profit | $8.0M | $10.0M | XXX | XXX | XXX |
| Gross Margin | 55% | 60% | XXX | XXX | XXX |
| EBITDA | -$3.2M | -$2.0M | XXX | XXX | XXX |
| EBITDA Margin | -22% | -12% | XXX | XXX | XXX |
| Net Profit | -$3.2M | -$4.2M | XXX | XXX | XXX |
| Net Margin | -22% | -25% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Cyclopharm's stock price is AUD 1 (or $1).
Cyclopharm has current market cap of AUD 162M (or $103M), and EV of AUD 150M (or $94.8M).
See Cyclopharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94.8M | $103M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Cyclopharm has market cap of $103M and EV of $94.8M.
Cyclopharm's trades at 4.7x LTM EV/Revenue multiple, and -16.3x LTM EBITDA.
Analysts estimate Cyclopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cyclopharm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $94.8M | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | -46.5x | XXX | XXX | XXX |
| P/E | -34.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -19.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCyclopharm's NTM/LTM revenue growth is 65%
Cyclopharm's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Cyclopharm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cyclopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cyclopharm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -36% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 53% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 53% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 99% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cyclopharm acquired XXX companies to date.
Last acquisition by Cyclopharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Cyclopharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cyclopharm founded? | Cyclopharm was founded in 2005. |
| Where is Cyclopharm headquartered? | Cyclopharm is headquartered in Australia. |
| How many employees does Cyclopharm have? | As of today, Cyclopharm has 87 employees. |
| Is Cyclopharm publicy listed? | Yes, Cyclopharm is a public company listed on ASX. |
| What is the stock symbol of Cyclopharm? | Cyclopharm trades under CYC ticker. |
| When did Cyclopharm go public? | Cyclopharm went public in 2007. |
| Who are competitors of Cyclopharm? | Similar companies to Cyclopharm include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Cyclopharm? | Cyclopharm's current market cap is $103M |
| What is the current revenue of Cyclopharm? | Cyclopharm's last 12-month revenue is $20.0M. |
| What is the current EBITDA of Cyclopharm? | Cyclopharm's last 12-month EBITDA is -$5.8M. |
| What is the current EV/Revenue multiple of Cyclopharm? | Current revenue multiple of Cyclopharm is 4.7x. |
| What is the current EV/EBITDA multiple of Cyclopharm? | Current EBITDA multiple of Cyclopharm is -16.3x. |
| What is the current revenue growth of Cyclopharm? | Cyclopharm revenue growth between 2023 and 2024 was 13%. |
| Is Cyclopharm profitable? | Yes, Cyclopharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
